The combination of the PD-L1 inhibitor benmelstobart, the angiogenesis inhibitor anlotinib, and the chemotherapies etoposide and carboplatin significantly improved progression-free survival and overall survival compared with the chemotherapies alone in patients with newly diagnosed extensive-stage small cell lung cancer. Both survival measures were longer than those seen with any other trials in this population of patients.

©2023 American Association for Cancer Research
2023
American Association for Cancer Research
You do not currently have access to this content.